Jane Huang Sells 1,600 Shares of BeiGene, Ltd. (BGNE) Stock
BeiGene, Ltd. (NASDAQ:BGNE) CMO Jane Huang sold 1,600 shares of BeiGene stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $86.25, for a total transaction of $138,000.00. Following the transaction, the chief marketing officer now directly owns 264,900 shares of the company’s stock, valued at $22,847,625. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Jane Huang also recently made the following trade(s):
- On Thursday, November 16th, Jane Huang sold 600 shares of BeiGene stock. The stock was sold at an average price of $85.00, for a total transaction of $51,000.00.
Shares of BeiGene, Ltd. (BGNE) opened at $85.04 on Wednesday. BeiGene, Ltd. has a twelve month low of $26.43 and a twelve month high of $118.95. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.33 and a quick ratio of 9.27.
BeiGene (NASDAQ:BGNE) last announced its earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $2.31. The business had revenue of $220.21 million for the quarter, compared to the consensus estimate of $1.55 million. During the same quarter in the prior year, the company earned ($1.08) EPS. equities analysts anticipate that BeiGene, Ltd. will post -3.09 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/jane-huang-sells-1600-shares-of-beigene-ltd-bgne-stock/1719276.html.
Several large investors have recently made changes to their positions in BGNE. SG Americas Securities LLC purchased a new stake in shares of BeiGene during the second quarter worth about $111,000. Quantbot Technologies LP purchased a new position in shares of BeiGene in the 3rd quarter worth approximately $160,000. Renaissance Technologies LLC purchased a new position in shares of BeiGene in the 1st quarter worth approximately $238,000. Profund Advisors LLC purchased a new position in shares of BeiGene in the 2nd quarter worth approximately $248,000. Finally, Teachers Retirement System of The State of Kentucky purchased a new position in shares of BeiGene in the 3rd quarter worth approximately $248,000. 57.07% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have recently commented on BGNE shares. Morgan Stanley reissued an “overweight” rating and issued a $95.00 price objective (up previously from $87.00) on shares of BeiGene in a research report on Friday, October 6th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $86.00 price objective (up previously from $43.00) on shares of BeiGene in a research report on Tuesday, August 15th. Zacks Investment Research cut shares of BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Maxim Group reissued a “buy” rating and issued a $120.00 target price (up previously from $77.00) on shares of BeiGene in a report on Thursday, September 28th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $83.00 target price (up previously from $58.00) on shares of BeiGene in a report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. BeiGene has a consensus rating of “Buy” and a consensus target price of $96.67.
BeiGene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.